PFE · Healthcare

PFIZER INC

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: everything published this earnings window

News · 2026-11-06

• Capital Expenditure ProgramImportance 46 · Surprise 42
  Pfizer plans to invest $650 million over five years to build a 220,000-square-foot manufacturing technology center at its Groton, Connecticut R&D campus. The facility is intended to produce clinical active…
• Manufacturing and CapacityImportance 46 · Surprise 42
  Pfizer plans to invest $650 million over five years in a 220,000-square-foot manufacturing technology center at its Groton, Connecticut R&D campus. The facility is expected to produce clinical active pharmaceutical…
• Domestic Manufacturing InvestmentImportance 46 · Surprise 42
  Third-party reports say Pfizer plans to invest $650 million over five years in a 220,000-square-foot manufacturing technology center at its Groton, Connecticut, R&D campus. The U.S. facility is expected to produce…

News · 2026-11-05

• CFO Leadership TransitionImportance 52 · Surprise 42
  Pfizer permanently appointed Cecile Guegan as executive vice president and chief financial officer. Guegan is a 20-year company veteran who held finance roles of increasing responsibility and will oversee corporate…
• Revenue Performance and MixImportance 47 · Surprise 60
  Pfizer reported Q3 2026 revenue of $16.6 billion, described as weaker than the prior-year quarter. Basic earnings per share was $0.57, and the report said adjusted earnings beat expectations. Adjusted EPS was flat year…
• Capital Expenditure ProgramImportance 40 · Surprise 42
  Pfizer plans to invest $650 million over five years in a manufacturing technology center at its Groton, Connecticut, research and development campus. The planned facility will cover 220,000 square feet and manufacture…
• Manufacturing and CapacityImportance 40 · Surprise 42
  Pfizer plans to invest $650 million over five years in a 220,000-square-foot manufacturing technology center at its Groton, Connecticut, research and development campus. The center will produce active pharmaceutical…
• DividendsImportance 14 · Surprise 6
  Pfizer's dividend was reported at $1.72 per share annually. The report characterized the dividend as well covered. It also stated that Pfizer's adjusted EPS remained flat year over year in Q3 2026, alongside weaker…

News · 2026-11-04

• Guidance and OutlookImportance 69 · Surprise 60
  Pfizer raised its 2026 revenue outlook to $62 billion–$64 billion and adjusted EPS outlook to $2.95–$3.05. Management said the company is on schedule to deliver virtually all of its targeted $7.2 billion in net savings…
• Guidance / OutlookImportance 63 · Surprise 60
  Pfizer raised its 2026 revenue forecast to $62 billion–$64 billion and adjusted diluted EPS forecast to $2.95–$3.05. Q3 2026 revenue was $16.6 billion and adjusted diluted EPS was $0.87, including a $0.10 Innovent…
• Strategic Cost SavingsImportance 58 · Surprise 42
  Pfizer said it was on schedule to deliver virtually all of its targeted $7.2 billion in net savings by the end of 2026. Management also reported meaningful progress with productivity initiatives during Q3 2026. The…
• Product Demand TrendsImportance 58 · Surprise 56
  Pfizer’s launched and acquired products generated $3.8 billion in Q3 2026 revenue, up 32% operationally. Padcev, Nurtec, and Lorbrena contributed $255 million, $135 million, and $114 million, respectively, while…
• Revenue Performance and MixImportance 52 · Surprise 56
  Pfizer reported Q3 2026 revenue of $16.6 billion, while non-COVID products grew 7% operationally as lower COVID-19 product revenue offset growth. Launched and acquired products generated $3.8 billion, up 32%…
• Acquisition / Partnership / DivestitureImportance 46 · Surprise 42
  United Therapeutics agreed to pay Pfizer subsidiary Arena Pharmaceuticals an upfront $525 million to eliminate all royalty obligations under its ralinepag license agreement. The buyout applies to all ralinepag…
• Strategic Portfolio RefocusImportance 46 · Surprise 42
  United Therapeutics agreed to pay Pfizer subsidiary Arena Pharmaceuticals $525 million upfront to eliminate all royalty obligations under its exclusive license agreement for ralinepag. The buyout removes a double-digit…
• Gross Margin DriversImportance 9 · Surprise 6
  Pfizer's adjusted gross margin was 77% in Q3 2026. The reported drivers were favorable product mix and cost management. The quarter's adjusted operating margin was 36%, tempered by a $0.10-per-share Innovent…

10-Q · 2026-11-03

• Intangible Asset ImpairmentsImportance 69 · Surprise 64
  For the nine months ended September 27, 2026, Pfizer’s reconciliation included a $4.325 billion adjustment for certain asset impairments. The comparable 2025 nine-month reconciliation showed a $577 million adjustment…
• Operating Cash Flow TrendsImportance 64 · Surprise 56
  Operating cash flow for the nine months ended September 27, 2026 increased to $8.825 billion from $6.356 billion in the prior-year period, a 39% increase. Pfizer attributed the increase mainly to the timing of…
• Restructuring ChargesImportance 58 · Surprise 42
  Pfizer announced an additional $1.0 billion of anticipated net savings from its Realigning Our Cost Base Program, bringing expected cumulative savings to approximately $6.7 billion through 2029; the additional savings…
• Manufacturing Footprint OptimizationImportance 58 · Surprise 42
  In the third quarter of 2026, Pfizer announced a new phase of its Manufacturing Optimization Program, focused on network structure changes, product portfolio enhancements and operational efficiencies. The phase is…
• Litigation and Legal RiskImportance 58 · Surprise 56
  For the first nine months of 2026, Pfizer recorded $1.0 billion of charges for certain legal matters, primarily product liability and other legal expenses. The comparable charges for the first nine months of 2025 were…
• Revenue Performance and MixImportance 57 · Surprise 64
  Third-quarter revenue was relatively flat, while revenue excluding Comirnaty and Paxlovid increased 7% operationally; nine-month revenue also increased 7% excluding those COVID-19 products. Demand and market-share…
• Trade Policy and TariffsImportance 53 · Surprise 60
  On April 2, 2026, the U.S. Government announced Section 232 tariffs of up to 100% on imported patented pharmaceuticals and their ingredients, citing national-security concerns about supply-chain reliance. The measures,…
• Metsera Acquisition SynergiesImportance 52 · Surprise 42
  Following the November 2025 acquisition of Metsera, Pfizer expects approximately $600 million in annual cost synergies by the end of 2026. The one-time costs to generate those synergies are expected to total…
• ViiV Investment ExitImportance 48 · Surprise 42
  Pfizer completed the sale of its 11.7% investment in ViiV on March 31, 2026, during its second fiscal quarter. The transaction generated $1.875 billion in cash proceeds. The sale contributed to a $1.870 billion net…
• Drug Pricing PolicyImportance 46 · Surprise 42
  Pfizer expects continued U.S. government and state attention to drug pricing and access, including international reference pricing and Most-Favored-Nation pricing. Under the Inflation Reduction Act’s Medicare Drug…
• Product Pipeline ProgressImportance 41 · Surprise 42
  Pfizer reported 2026 U.S. approval of Veppanu (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer and U.S. and EU approvals expanding Padcev and other products into additional treatment…
• Acquired In-Process R&D ExpenseImportance 34 · Surprise 42
  Acquired in-process research and development expense declined $722 million in the third quarter and $579 million in the first nine months of 2026. The 2026 expense included a $650 million charge for an in-licensing and…
• Research and Development ExpenseImportance 32 · Surprise 24
  Research and development expense increased $469 million in the third quarter and $1.1 billion in the first nine months of 2026. Spending on certain oncology and obesity candidates rose $230 million in the quarter and…
• OECD Global Minimum TaxImportance 26 · Surprise 24
  Countries outside the U.S. have enacted global minimum tax legislation under the OECD’s Base Erosion and Profit Shifting Pillar Two project, with provisions generally effective for Pfizer since 2024. The company says…
• Share Repurchase ProgramImportance 26 · Surprise 24
  Pfizer had $3.3 billion remaining under its share-purchase authorization as of September 27, 2026. The company made no share repurchases in the first nine months of 2026. Pfizer’s capital allocation framework says…
• Capital Allocation StrategyImportance 26 · Surprise 24
  Pfizer’s capital allocation framework prioritizes reinvestment in the business, maintaining and over the long term growing its dividend, and potentially resuming share repurchases after de-leveraging. The company…
• Liquidity and Debt PositionImportance 25 · Surprise 6
  Pfizer reported access to a $7.0 billion committed revolving credit facility maturing in October 2031 and an additional $220 million of lender-provided lines of credit. All credit lines were unused as of the filing…
• Net Income and ProfitabilityImportance 24 · Surprise 14
  Income from continuing operations before taxes increased $51 million to $3.4 billion in the third quarter of 2026 from $3.3 billion a year earlier. The quarterly comparison benefited from lower cost of sales and…
• Other Income and ImpairmentsImportance 23 · Surprise 6
  Other income and deductions showed a favorable $229 million period-over-period change in the third quarter, reflecting the non-recurrence of a prior-year intangible impairment, lower legal charges, higher…
• Gross Margin DriversImportance 18 · Surprise 14
  Cost of sales fell $144 million in the third quarter to $4.028 billion, and its share of revenue declined to 24.3% from 25.0%. The quarterly decrease reflected a $340 million favorable sales-mix change and $170 million…
• Operating Expense TrendsImportance 18 · Surprise 14
  Selling, informational and administrative expenses rose $93 million in the third quarter to $3.279 billion, including $100 million higher compensation costs, $40 million from a lower favorable U.S. healthcare reform…
• Income Tax Rate ChangesImportance 17 · Surprise 24
  Pfizer’s effective tax rate on continuing operations was 3.9% in the third quarter of 2026, compared with (6.5)% in the third quarter of 2025. The nine-month effective rate was 3.2%, versus (2.9)% in the prior-year…
• Supply Chain ConstraintsImportance 7 · Surprise 6
  Pfizer reported no significant supply-chain disruption during the first nine months of 2026 or through the filing date, with substantially all global manufacturing sites operating at or near normal levels. The company…
• DividendsImportance 7 · Surprise 6
  In October 2026, Pfizer’s board declared a dividend of $0.43 per share. The dividend is payable December 7, 2026, to shareholders of record at the close of business on November 6, 2026.

Earnings call · 2026-11-03

• Strategic Cost SavingsImportance 58 · Surprise 42
  Pfizer remained on track to deliver nearly all of its anticipated $7.2 billion in net savings by the end of 2026 from ongoing cost-improvement programs. The next phase is expected to generate an additional $2.5 billion…
• Operating Expense TrendsImportance 54 · Surprise 40
  Third-quarter adjusted operating expenses were $6.8 billion. Adjusted SI&A expense rose 2% operationally, partly because of a smaller favorable U.S. healthcare reform fee adjustment, while lower targeted marketing and…
• Oncology Portfolio GrowthImportance 52 · Surprise 56
  Pfizer said its legacy Seagen portfolio grew 39% year over year in the U.S., driven by Padcev, and that acquired products overall grew 37% operationally. Management said combining Seagen medicines with Pfizer’s…
• Migraine Product DevelopmentImportance 52 · Surprise 56
  Biohaven grew 33% operationally in the quarter, with management citing underlying demand and commercial execution. Pfizer said it leads the oral CGRP class in the U.S. and is working to extend that position…
• Acquisition / Partnership / DivestitureImportance 46 · Surprise 42
  Management said Pfizer’s business-development focus is on bolt-on acquisitions that complement its portfolio in four therapeutic areas, rather than prioritizing another large transaction. It cited approximately $6…
• Guidance / OutlookImportance 44 · Surprise 24
  Pfizer plans to provide 2027 guidance around mid-December, with LOE impacts from Ibrance and Xtandi in the U.S. and Eliquis internationally at the end of 2026. Management said growth from launched and acquired products…
• Capital Allocation StrategyImportance 44 · Surprise 24
  Pfizer’s stated priorities are to reinvest in the business at appropriate returns, maintain and over time grow its dividend, and preserve flexibility for shareholder returns including share repurchases. After the…
• Revenue Performance and MixImportance 38 · Surprise 24
  CEO Albert Bourla said Nurtec was close to $2 billion on an annualized basis, while the Street forecast it to reach almost $2.5 billion by 2030. He contrasted a $5 billion Street forecast for a competing product with a…
• Liquidity and Debt PositionImportance 37 · Surprise 6
  Third-quarter year-to-date 2026 operating cash flow was $8.8 billion. Leverage ended the quarter at 2.6 times, slightly below Pfizer’s 2026 target of 2.7 times. Management expects leverage to remain around current…
• China Market AccessImportance 34 · Surprise 42
  Pfizer said it introduced ecnoglutide in China at the end of April 2026 and received approval for its type 2 diabetes indication at the end of October, opening access to hospital and, under local regulations,…
• Regulatory Approval MilestonesImportance 34 · Surprise 42
  Pfizer and Valneva’s Lyme disease vaccine candidate has had its marketing authorization application validated by the European Medicines Agency, allowing the CHMP assessment to begin. The CHMP is expected to issue an…
• Drug Pricing PolicyImportance 32 · Surprise 24
  Management said it expects no major legislative movement in 2027 and does not expect changes to the U.S. most-favored-nation (MFN) agreements, which it said remain in place through the end of the current government’s…
• Gross Margin DriversImportance 31 · Surprise 6
  Third-quarter adjusted gross margin was 77%, supported primarily by favorable product mix and continued cost management. Adjusted operating margin was 36%, reflecting strong non-COVID revenue, effective cost…
• Product / Drug Pipeline ProgressImportance 30 · Surprise 24
  Pfizer is developing tilrekimig, an in-house trispecific antibody targeting IL-4, IL-13, and TSLP, for atopic dermatitis and other type 2 inflammatory diseases. Phase 2 results showed a placebo-adjusted EASI-75…
• Products and TechnologyImportance 30 · Surprise 24
  Pfizer is advancing atermaciclib as a potential next-generation treatment backbone in first-line and early HR-positive breast cancer, positioning its CDK4 selectivity against tolerability limitations of existing CDK4/6…
• Oncology Pipeline ProgressImportance 30 · Surprise 24
  Pfizer is expanding development of tivonatinib, a PD-1/VEGF bispecific, with more than 1,200 patients treated globally and two Phase 3 trials underway; two additional Phase 3 trials were expected to begin that year. In…
• Next-Generation Pneumococcal VaccineImportance 30 · Surprise 24
  Pfizer reported that pediatric PCV25 Phase 2 results met the historical twofold post-dose IgG criterion for all 20 serotypes shared with Prevnar 20. The company’s Phase 3 design incorporates a more stringent FDA…
• New Product Market GrowthImportance 26 · Surprise 24
  Management attributed its growth trajectory in part to continued growth of new and acquired products, citing expanding markets, increasing penetration and opportunities to add indications and reach more patients. It…
• Distribution Channels and PartnershipsImportance 23 · Surprise 24
  Management said obesity products have a consumer-oriented commercial model, with patients willing to pay out of pocket for products they value even without reimbursement. It sees e-commerce and the internet as…
• Lyme Vaccine Commercial OpportunityImportance 23 · Surprise 24
  Management said the burden of Lyme disease is increasing globally and described the vaccine candidate partnered with Valneva as a commercial opportunity. Pfizer expects to draw on its European TicoVac franchise, sales…